Tyvaso DPI: Drug-device characteristics and patient clinical considerations

By sjmartinez • November 16, 2023

McEvoy C, Argula R, Sahay S, Shapiro S, Eagan C, Hickey AJ, Smutney C, Dillon C, Winkler T, Davis B, Broderick M, Burger C. Tyvaso DPI: Drug-device characteristics and patient clinical considerations. Pulm Pharmacol Ther. 2023 Nov 13:102266. doi: 10.1016/j.pupt.2023.102266. Epub ahead of print. PMID: 37967762.

Tags: Cardiology/Epi, Inhaled, prostacyclin, Publications, pulmonary arterial hypertension, pulmonary drug delivery, Pulmonary hypertension with interstitial lung disease, Treprostinil, Veterans Administration

Year 2. December 4. Fellowship Match Results Confirms that UCLA DoM is Among the Best in the Country.

Within the Department of Medicine (DoM) at UCLA, trainees are the heartbeat of our community. The medical students, residents, fellows, and postdocs who make up ...

Epitranscriptomic Modification of MicroRNA Increases Atherosclerosis Susceptibility

He M, Dong J, Wen J, Zhang Y, Han SY, Wang C, Gongol B, Wei TW, Kang J, Huang HY, Cheng S, Shyy JY. Epitranscriptomic ...

Gene Regulatory Networks in Coronary Artery Disease

Cheng J, Cheng M, Lusis AJ, Yang X. Gene Regulatory Networks in Coronary Artery Disease. Curr Atheroscler Rep. 2023 Nov 27. doi: 10.1007/s11883-023-01170-7. Epub ahead ...